Pharming Technologies B.v.

This study is testing a drug called leniolisib in very young children (ages 1 to 6) who have a rare genetic immune disorder called APDS. The goal is to see if the drug is safe and effective at controlling the disease by reducing swollen lymph nodes and infections. The children wi…

This study is testing a medication called leniolisib in children aged 4 to 11 who have a rare genetic immune disorder called APDS. The main goals are to see if the drug is safe for children, how their bodies process it, and if it can help reduce swollen lymph nodes and infections…

This study is testing an oral drug called leniolisib in about 20 people with Common Variable Immunodeficiency (CVID) who also have specific immune system overactivity problems. The main goal is to see if the drug is safe and well-tolerated when taken for 6 months at increasing do…

This study is testing a drug called leniolisib to see if it is safe and tolerable for people with specific, rare genetic disorders that cause the immune system to malfunction. The study will involve about 12 participants, aged 12 to 75, who have one of these disorders and related…